Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

Summary

A multi-center controlled, non-comparative open Phase II trial of docetaxel and celecoxib in patients with metastatic androgen independent prostate cancer where efficacy is measured by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart.

Timeline

Start

2004-11

Primary completion

2005-04

Completion

2005-04

Outcome

Outcome not reported

Stopped: “due to celecoxib safety issues”

Drugs

Indications